ESAB Corporation shares surged 5.12% intraday on Thursday following the release of its second-quarter 2026 earnings, which showcased strong sales performance and an upgraded full-year outlook.

The industrial compounder reported Q2 sales of $808 million, comfortably surpassing the consensus estimate of $758 million. Core adjusted EBITDA rose 8% to $150 million, driven by organic growth in North America and Asia, alongside resilient performance in Europe. Despite a slight miss on adjusted earnings per share—$1.33 versus the expected $1.38—investors focused on the company’s enhanced guidance and the ahead-of-schedule closing of the Eddyfi acquisition.

ESAB raised its full-year 2026 core net sales growth forecast to 11%–14%, up from a prior range of 6%–9%, and lifted its core adjusted EBITDA forecast to $615–$625 million. Management expressed confidence in mitigating transitory cost inflation and reaffirmed its commitment to long-term financial targets, further buoying market sentiment.